RESprotect GmbH Information

RESprotect GmbH is a privately owned biotechnology company located in Dresden Germany. RESprotect is focusing on the inhibition of chemoresistance and the enhancement of chemosensivity. In contrast to the well know efforts to circumvent or decrease existing chemoresistance, this basic approach is unrivalled. Chemogenomics, the approach of RESprotect, focuses on the applicationof small synthetic molecules, which elicit favorable phenotypicchanges. The combination with genomic tools concentrating on specificbiological pathways allows a better understanding of the broader effectof the drug. By doing so, it is possible to discover drugs that targetthe cause of a disease rather than ist symptoms. RESprotect's compoundsare given additionally to standard chemotherapy. Chemotherapy reliesupon the induction of apoptosis (self inflicted death) of tumor cells,which is the main anti-cancer mechanism. One major problem inchemotherapeutic treatment is the induction of chemoresistance, whichantagonizes the apoptosis of cancer cells. The chemogenomics approachof RESprotect resulted in the identification of a number of validatedtargets contributing to the development of chemoresistance byantagonizing apoptosis. RP101, the Company's first small molecule drugcandidate, suppresses the over-expression of apoptosis-antagonizinggene products induced by cytostatic drug treatment.